Related references
Note: Only part of the references are listed.Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B
Patrick Marcellin et al.
HEPATOLOGY (2008)
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B
Michael W. Fried et al.
HEPATOLOGY (2008)
Virological and biochemical response in patients with HBeAG-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) with or without lamivudine: Results of 4-year follow-up
P. Marcellin et al.
JOURNAL OF HEPATOLOGY (2008)
Hepatitis B: Reflections on the current approach to antiviral therapy
Fabien Zoulim et al.
JOURNAL OF HEPATOLOGY (2008)
A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B
Robert G. Gish et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2007)
Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
F. Bonino et al.
GUT (2007)
Management of hepatitis B: Summary of a clinical research workshop
Jay H. Hoofnagle et al.
HEPATOLOGY (2007)
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years
Stephanos J. Hadziyannis et al.
GASTROENTEROLOGY (2006)
Therapy of hepatitis B - Viral suppression or eradication?
RP Perrillo
HEPATOLOGY (2006)
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B
P Marcellin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy
B Werle-Lapostolle et al.
GASTROENTEROLOGY (2004)
Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy
P Lampertico et al.
HEPATOLOGY (2003)
Share Paper
